MEDIPOST recently obtained a patent in Canada for its composition for treating lung diseases.

The title of this patent is ‘Composition for treating developmental and/or chronic lung diseases comprising cells separated or proliferated from umbilical cord blood’.

MEDIPOST is currently using this technology for its ‘PNEUMOSTEM^®’ currently in clinical trials for treating bronchial pulmonary dysplasia in premature babies.

MEDIPOST has already obtained a patent for this technology in Korea, Japan and Singapore.